Fortress Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
Fortress Biotech, Inc. (Nasdaq: FBIO) filed a Current Report on Form 8-K dated December 15, 2025. The filing reports a significant regulatory milestone regarding the Company's New Drug Application (NDA) for CUTX-101.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary event reported is the U.S. Food and Drug Administration's (FDA) acceptance of the resubmission of the NDA for CUTX-101 as a Class 1 resubmission. Consequently, the FDA has established a Prescription Drug User Fee Act (PDUFA) target action date of January 14, 2026.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA's acceptance of the NDA resubmission and the assignment of the PDUFA date. The filing does not provide updated financial guidance, discuss specific risks, or detail contingencies beyond the regulatory timeline for CUTX-101.
Key Facts for Investor Verification
- The FDA accepted the Class 1 resubmission of the NDA for CUTX-101 on December 15, 2025.
- The PDUFA target action date for the NDA is set for January 14, 2026.
- The full text of the press release is included as Exhibit 99.1 to this filing.
- No financial performance data is included in this specific report.